Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 121-133 , March 2010

A survey of therapy for advanced renal cell carcinoma

Received 2 March 2009 ,Revised 22 April 2009 ,Accepted 23 April 2009.

References 

  1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med. 1996;335:865–875
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  3. Ferlay J, Autier P, Boniol M, et al. Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74–108
  5. Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear cell renal carcinoma. J Natl Cancer Inst. 2002;94:1569–1575
  6. Soccio RE, Adam RM, Maxwell KN, et al. Differential gene regulation of star D4 and star D5 cholesterol transfer protein (Activation of starD4 by sterol regulatory element binding protein-2 and starD5 by endoplasmic reticulum stress). J Biol Chem. 2005;280:19410–19418
  7. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004
  8. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028–1043
  9. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–4380
  10. Kaufmann JJ. Cancer of the urogenital tract: Kidney (Reasons from nephrectomy: Palliative and curative). JAMA. 1968;204:607–608
  11. Montie JE, Stewart BH, Straffon RA, et al. The role of adjuvant nephrectomy in patients in patients with metastatic renal cell carcinoma. J Urol. 1977;3:272–275
  12. Wood CG. The role of cytoreductive nephrectomy in the management of the metastatic renal cell carcinoma. Urol Clin North Am. 2003;30:581–588
  13. Flanigan RC, Salmon SE, Blumestein BA, et al. Nephrectomy followed by interferon-α 2b compared with interferon-α 2b alone for metastatic renal-cell cancer. N Eng J Med. 2001;345:1655–1659
  14. Mickisch GH, Garim A, van Poppel H, et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal-cell carcinoma: Randomized trial. Lancet. 2001;358:966–970
  15. Kierney PC, Van Heerden JA, Segura JW, et al. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: An institutional review. Ann Surg Oncol. 1994;1:345–352
  16. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261–2266
  17. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic site rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314–319
  18. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: Is it worthwhile?. Ann Surg Oncol. 2003;10:705–710
  19. Hofmann NE, Gillett MD, Cheville JC, et al. Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol. 2008;179:474–477
  20. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol. 1995;22:42–60
  21. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal cell carcinoma. Br J Cancer. 2004;91:1763–1768
  22. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101:1545–1551
  23. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal cell carcinoma after non-myeloablative allogenic peripheral blood stem cell transplantation. N Eng J Med. 2000;343:750–758
  24. Rini BI, Halabi S, Barrier R, et al. Adoptive immunotherapy by allogenic stem cell transplantation for metastatic renal cell carcinoma: A CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006;12:778–785
  25. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  26. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004;4:455–468
  27. Dutcher JP, Atkins MB, Fischer R, et al. Interleukin-2 based therapy for metastatic renal cell cancer: The Cytokine Working Group Study experience. Can J Sci Am. 1997;3:S73–S78
  28. Dutcher JP, Fischer RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-α for metastatic renal cell cancer: Five years follow-up of the Cytokine Working Group Study. Cancer J Sci Am. 1997;3:157–162
  29. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin-2, interferon-α, and 5-fluorouracil in metastatic renal cell cancer: A cytokine working group study. Clin Cancer Res. 2000;6:3442–3450
  30. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous interleukin-2 and interferon-α with or without fluorouracil (Groupe Francais d'immunotherapie, Federation nationale des centres de lutte contre le cancer). J Clin Oncol. 2000;15:4007–4008
  31. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon-α 2a, or both in metastatic renal cell carcinoma. N Eng J Med. 1998;338:1272–1278
  32. McDermott DF, Regan M, Clark J, et al. Randomized phase III trial of high-dose interleukin-2 vs. subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–141
  33. Yang J, Sherry R, Steinberg S, et al. Randomized study of high-dose and low dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–3132
  34. Collaborators MRC. Interferon-α and survival in metastatic renal carcinoma (Early results of a randomized controlled trial). Lancet. 1999;353:14–17
  35. McDermott D, Flaherty L, Clark J, et al. A randomized phase III trial of high-dose interleukin-2 (HD IL2) vs. subcutaneous (SC) IL2/interferon (INF) in patients with metastatic renal cell carcinoma (RCC) (A Cytokine Working Group Study). Proc Am Soc Clin Oncol. 2001;2072a
  36. Atkins MB, Regan M, McDermott DF. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004;(Suppl):S6342–S6346
  37. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987;14(Suppl 2):36–42
  38. Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer. 1986;57(Suppl 8):1696–1699
  39. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (RCC) of intermediate prognosis? (Results of the prospective randomized PERCY Quattro trial). J Clin Oncol. 2005;23:DBA4511;[Abstract]
  40. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon-α 2a plus vinblastine vs. vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859–2867
  41. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  42. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;15:6388–6392
  43. Carlomagno F, Anaganti S, Guida T, et al. BAY 34-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334
  44. Chang YS, Henderson A, Xue D, et al. BAY 43-9006 (sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. AACR Meeting Abstracts. 2005;1372:
  45. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel RAF kinase and vascular endothelial growth factor receptor inhibitor BAY 439006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–972
  46. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505–2512
  47. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med. 2007;356:125–134
  48. Szczylik C, Dmkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib vs. interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol. 2007;25:5025;[Abstract]
  49. Ryan C, Goldman B, Lara P, et al. Sorafenib with interferon α-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group. J Clin Oncol. 2007;25:3296–3301
  50. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factors receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337
  51. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine inhibitor in patients with cancer. J Clin Oncol. 2006;24:25–35
  52. O'Farrel AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9:5465–5476
  53. Schuenermann AJ, Himmerlfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor re-growth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63:4009–4016
  54. Raymond E, Faivre S, Vera C, et al. Final results of a phase I and pharmacokinetic study of SU111248, a novel multitarget tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol. 2003;22:769;[Abstract]
  55. Motzer R, Michaelson D, Redman B, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  56. Motzer R, Rini B, Bukowski R, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–2524
  57. Motzer R, Hutson T, Tomczak P, et al. Sunitinib vs. interferon-α in metastatic renal cell carcinoma. N Eng J Med. 2007;356:115–124
  58. Presta LG, Chen H, O'Connor SJ, et al. Humanization of antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–4599
  59. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med. 2004;350:2335–2342
  60. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Eng J Med. 2006;355:2542–2550
  61. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N Eng J Med. 2003;349:427–434
  62. Escudier B, Pluzanka A, Koralewski P, et al. Bevacizumab plus interferon-α 2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet. 2007;370:2103–2111
  63. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-(α) 2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008;19:1470–1476
  64. Schmezle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253–262
  65. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effector S6K1 and 4E-BP1 eukaryotic translation factor 4E. Mol Cell Biol. 2004;24:200–216
  66. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1-α expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004–7014
  67. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122–127
  68. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Anti-angiogenic potential of mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549–5554
  69. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor in patients with cancer. J Clin Oncol. 2004;22:2336–2347
  70. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res. 2006;12:5755–5763
  71. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–918
  72. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-α, or both for advanced renal cell carcinoma. N Eng J Med. 2007;356:2271–2281
  73. Schmidinger M, Vogl UM, Lamm W, et al. Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: Preliminary results from the Austrian Compassionate Use Program. J Clin Oncol. 2008;26(Suppl 20):16125;[Abstract]
  74. Jac J, Giessinger S, Khan M, et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (MRCC). J Clin Oncol. 2007;25(Supp S18):5107;[Abstract]
  75. Jac J, Amato J, Giessinger S, et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol. 2008;26(Suppl 20):LBA5026;[Abstract]
  76. Motzer RJ, Escudier B, Oudard S, et al. RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: A double blind randomized, placebo-controlled phase III trial. Lancet. 2008;372:449–456
  77. Feldman DR, Ginsberg MS, Baum M, et al. Phase I trial bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(Suppl 20):5100;[Abstract]
  78. Fischer P, Patel P, Carducci MA, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol. 2008;26(Suppl 20):16020;[Abstract]
  79. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol. 2008;26(Suppl 20):5011;[Abstract]
  80. Whorf RC, Haisnwhort JD, Spiegel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol. 2008;26(Suppl 20):5010;[Abstract]
  81. Bracarda S, Porta C, Boni C, et al. GOIRC Study Group Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2a (IFN) in metastatic renal carcinoma (RAPSODY): GOIRC study 0681. J Clin Oncol. 2007;25(Suppl S18):5100;[Abstract]
  82. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol. 2002;20:2376–2381
  83. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127–131
  84. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol. 2007;25(Suppl 18S):5010;[Abstract]
  85. Knox JJ, Figlin RA, Stadler WM, et al. The advanced renal cell carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oncol. 2007;25(Suppl 18S):5011;[Abstract]
  86. Beck J, Bajetta E, Escudier BS, et al. A large open-label, noncomparative phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer Suppl. 2007;5(Suppl):300;4506 [Abstarct]
  87. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-α (IFN). J Clin Oncol. 2007;25(Suppl 18S):5033;[Abstract]
  88. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon α-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern cooperative oncology group/intergroup trial. J Clin Oncol. 2003;21:1214–1222
  89. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol. 2003;21:3133–3140
  90. Bex A, van der Veldt AA, Balnk C, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: Initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;Jan 15:[Epub ahead of print]
  91. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib vs. interferon (IFN)-α as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26:5024;[Abstract]
  92. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-α as comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–296
  93. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based therapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3:S192–S197
  94. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer. 2003;98:2566–2575
  95. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2 base therapy. J Immunother. 2005;28:488–495
  96. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811
  97. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714–3721
  98. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–296
  99. Mekhail TM, Abou-Jawde RN, BouMerhi G, et al. Validation and extension of Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–841

PII: S1078-1439(09)00142-2

doi: 10.1016/j.urolonc.2009.04.015

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 121-133 , March 2010

Article Tools